Chemistry, structure and function of approved oligonucleotide therapeutics
M Egli, M Manoharan - Nucleic Acids Research, 2023 - academic.oup.com
Eighteen nucleic acid therapeutics have been approved for treatment of various diseases in
the last 25 years. Their modes of action include antisense oligonucleotides (ASOs), splice …
the last 25 years. Their modes of action include antisense oligonucleotides (ASOs), splice …
Accelerating antiviral drug discovery: lessons from COVID-19
During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and
collaborative drug discovery efforts took place in academia and industry, culminating in …
collaborative drug discovery efforts took place in academia and industry, culminating in …
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
TKH Scheel, CM Rice - Nature medicine, 2013 - nature.com
More than two decades of intense research has provided a detailed understanding of
hepatitis C virus (HCV), which chronically infects 2% of the world's population. This effort has …
hepatitis C virus (HCV), which chronically infects 2% of the world's population. This effort has …
Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics
No therapeutics or vaccines currently exist for human coronaviruses (HCoVs). The Severe
Acute Respiratory Syndrome-associated coronavirus (SARS-CoV) epidemic in 2002–2003 …
Acute Respiratory Syndrome-associated coronavirus (SARS-CoV) epidemic in 2002–2003 …
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
R Bartenschlager, V Lohmann, F Penin - Nature Reviews Microbiology, 2013 - nature.com
The availability of the first molecular clone of the hepatitis C virus (HCV) genome allowed
the identification and biochemical characterization of two viral enzymes that are targets for …
the identification and biochemical characterization of two viral enzymes that are targets for …
Preparing for the next viral threat with broad-spectrum antivirals
There is a large global unmet need for the development of countermeasures to combat
hundreds of viruses known to cause human disease and for the establishment of a …
hundreds of viruses known to cause human disease and for the establishment of a …
Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses
L Eyer, R Nencka, E de Clercq… - Antiviral Chemistry …, 2018 - journals.sagepub.com
Nucleoside analogs represent the largest class of small molecule-based antivirals, which
currently form the backbone of chemotherapy of chronic infections caused by HIV, hepatitis …
currently form the backbone of chemotherapy of chronic infections caused by HIV, hepatitis …
Nucleotide analogues as inhibitors of SARS‐CoV polymerase
J Ju, X Li, S Kumar, S Jockusch… - Pharmacology …, 2020 - Wiley Online Library
Abstract SARS‐CoV‐2, a member of the coronavirus family, has caused a global public
health emergency. Based on our analysis of hepatitis C virus and coronavirus replication …
health emergency. Based on our analysis of hepatitis C virus and coronavirus replication …
Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective
M Seifert, SC Bera, P Van Nies, RN Kirchdoerfer… - Elife, 2021 - elifesciences.org
The absence of 'shovel-ready'anti-coronavirus drugs during vaccine development has
exceedingly worsened the SARS-CoV-2 pandemic. Furthermore, new vaccine-resistant …
exceedingly worsened the SARS-CoV-2 pandemic. Furthermore, new vaccine-resistant …
Dengue drug discovery: Progress, challenges and outlook
SP Lim - Antiviral research, 2019 - Elsevier
In the context of the only available vaccine (DENGVAXIA) that was marketed in several
countries, but poses higher risks to unexposed individuals, the development of antivirals for …
countries, but poses higher risks to unexposed individuals, the development of antivirals for …